

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 31/135	A1	(11) International Publication Number: WO 94/00114 (43) International Publication Date: 6 January 1994 (06.01.94)
(21) International Application Number: PCT/US93/05966		(81) Designated States: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 22 June 1993 (22.06.93)		
(30) Priority data: 903,040 23 June 1992 (23.06.92) US		Published <i>With international search report.</i>
(71) Applicant: SEPRACOR INC. [US/US]; 33 Locke Drive, Marlborough, MA 01752 (US).		
(72) Inventor: YOUNG, James, W. ; 295 Still River Road, Still River, MA 01467 (US).		
(74) Agents: LAWRENCE, Stanton, T., III et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).		
(54) Title: METHODS AND COMPOSITIONS FOR TREATING DEPRESSION AND OTHER DISORDERS USING OPTICALLY PURE (-) SIBUTRAMINE		
(57) Abstract Methods and compositions are disclosed utilizing the optically pure (-) isomer of sibutramine, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. Further, methods and compositions are disclosed utilizing optically pure (-) sibutramine in order to avoid the adverse effects associated with the administration of racemic sibutramine.		